IO Biotech Presents Late-Breaking Abstract at ESMO Congress 2025

IO Biotech will present late-breaking data at the European Society for Medical Oncology Congress. The company will highlight results from a Phase 3 trial of IO102-IO103 cancer vaccine plus pembrolizumab for first-line advanced melanoma and present final data from a Phase 2 basket trial of the same combination for first-line treatment of solid tumors.

IO Biotech (Nasdaq: IOBT) has announced that it will present late-breaking data at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. The company will highlight results from a Phase 3 trial evaluating IO102-IO103 cancer vaccine plus pembrolizumab for first-line advanced melanoma, and present final data from a Phase 2 basket trial of the same combination for first-line treatment of solid tumors.

The oral presentation, scheduled for October 19-20, 2025, will feature results from the randomized Phase 3 trial assessing the efficacy and safety of IO102-IO103 in combination with pembrolizumab versus pembrolizumab monotherapy in first-line advanced melanoma. The Phase 2 basket trial will present updated efficacy and safety data, including median progression-free survival (PFS), landmark PFS, overall survival, and biomarker data for non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN).

IO Biotech's selection as a late-breaking abstract signifies the potential significance of the data presented. Late-breaking abstracts at ESMO are typically reserved for high-quality, new research findings from randomized Phase 2 or Phase 3 trials with implications for clinical practice or understanding of disease processes IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025^[1].

The timing of these presentations will be crucial for IO Biotech. Positive Phase 3 data could accelerate regulatory approval, while compelling Phase 2 data could support expansion into additional indications. The company's Phase 3 trial (IOB-013/KN-D18) has already completed enrollment and reported topline results in the third quarter of 2025 .

IO Biotech's Cylembio®, an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate, is designed to target both tumor cells and immune-suppressive cells in the tumor microenvironment. The company is conducting multiple clinical trials to evaluate Cylembio in combination with pembrolizumab for various solid tumors .